Search results
Your search for cost benefrt of cancer drugs returned no results
Showing 406 to 420 of 483 results for cost benefit of cancer drugs
Showing 406 to 420 of 483 results for cost benefit of cancer drugs
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Before 2022, we used different processes for assessing technologies. You can view the previous process and methods guides below.
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.